
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11949940/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients With Ongoing or Recent Alcohol Withdrawal. Clinical Gastroenterology and Hepatology, 2022, 20, 1542-1552.e6.	4.4	10
2	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis and Cannabinoid Research, 2022, 7, 677-689.	2.9	6
3	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Reports, 2022, 4, 100390.	4.9	15
4	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infectious Diseases, 2022, 22, 94.	2.9	6
5	ABO blood group does not influence Childâ€Pugh A cirrhosis outcome: An observational studyÂfrom CIRRAL and ANRS CO12 CIRVIR cohorts. Liver International, 2022, 42, 1386-1400.	3.9	2
6	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Reports, 2022, 4, 100481.	4.9	3
7	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. Journal of Cannabis Research, 2022, 4, .	3.2	1
8	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101459.	1.5	4
9	HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management. Cancer Prevention Research, 2021, 14, 581-592.	1.5	2
10	Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. JHEP Reports, 2021, 3, 100285.	4.9	4
11	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101713.	1.5	10
12	Personalized surveillance for hepatocellular carcinoma in cirrhosis– using machine learning adapted to HCV status. Journal of Hepatology, 2020, 73, 1434-1445.	3.7	52
13	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. Journal of Hepatology, 2020, 73, 1046-1062.	3.7	79
14	Iron metabolism imbalance at the time of listing increases overall and infectious mortality after liver transplantation. World Journal of Gastroenterology, 2020, 26, 1938-1949.	3.3	3
15	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infectious Diseases, 2019, 19, 300.	2.9	5
16	Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology, 2019, 156, 997-1009.e5.	1.3	100
17	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet, The, 2019, 393, 1453-1464.	13.7	449
18	Nonâ€virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of <scp>ANRS CO</scp> 12 CirVir cohort. Journal of Viral Hepatitis, 2019, 26, 384-396.	2.0	16

#	Article	IF	CITATIONS
19	Reduced phenotypic expression in genetic hemochromatosis with time: Role of exposure to non-genetic modifiers. Journal of Hepatology, 2019, 70, 118-125.	3.7	15
20	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology, 2018, 68, 1245-1259.	7.3	33
21	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. American Heart Journal, 2018, 198, 4-17.	2.7	49
22	Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2018, 16, 290-291.	4.4	16
23	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology, 2018, 155, 1436-1450.e6.	1.3	183
24	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology, 2018, 155, 431-442.e10.	1.3	81
25	Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir) Tj ETQq1 1 0.784314	rgBT /Ove 12.1	rlock 10 Tf
26	Worse Outcomes of Patients With HFE Hemochromatosis With Persistent Increases in Transferrin Saturation During Maintenance Therapy. Clinical Gastroenterology and Hepatology, 2017, 15, 1620-1627.	4.4	32
27	Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver International, 2017, 37, 1314-1324.	3.9	68
28	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. Journal of Hepatology, 2017, 66, 39-47.	3.7	100
29	Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology, 2017, 152, 142-156.e2.	1.3	420
30	Pretransplant renal function according to <scp>CKD</scp> â€ <scp>EPI</scp> cystatin C equation is a prognostic factor of death after liver transplantation. Liver International, 2016, 36, 547-554.	3.9	22
31	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology, 2016, 64, 1136-1147.	7.3	75
32	Chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2016, 28, 164-172.	1.6	3
33	Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. Journal of Hepatology, 2015, 62, 682-689.	3.7	51
34	Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir) Tj ETQq0 0 0 rgBT	/9.yerlock	10 Tf 50 14
35	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRILIS) Lancet Infectious Diseases. The 2015, 15, 397-404	9.1	267

³⁶Nonâ€invasive assessment of liver fibrosis in C282Y homozygous <scp>HFE</scp> hemochromatosis.3.93936Liver International, 2015, 35, 1731-1738.3.939

#	Article	IF	CITATIONS
37	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet, The, 2015, 385, 1075-1086.	13.7	281
38	SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 3429-3436.	3.2	13
39	Long-term course after initial iron removal of iron excess in patients with dysmetabolic iron overload syndrome. European Journal of Gastroenterology and Hepatology, 2014, 26, 418-421.	1.6	5
40	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. Gastroenterology, 2014, 147, 132-142.e4.	1.3	232
41	Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis. Journal of Hepatology, 2014, 60, 245-252.	3.7	58
42	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890. Journal of Hepatology, 2013, 59, 434-441.	3.7	407
43	Effect of alcohol consumption on liver stiffness measured by transient elastography. World Journal of Gastroenterology, 2013, 19, 516.	3.3	62
44	A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. Journal of Hepatology, 2012, 56, 334-340.	3.7	34
45	Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin. Antiviral Therapy, 2012, 17, 927-932.	1.0	3
46	Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. Journal of Hepatology, 2011, 54, 1130-1136.	3.7	57
47	Antiviral Activity of Danoprevir (ITMN-191/RG7227) in Combination With Pegylated Interferon α-2a and Ribavirin in Patients With Hepatitis C. Journal of Infectious Diseases, 2011, 204, 601-608.	4.0	19
48	A robust collagen scoring method for human liver fibrosis by second harmonic microscopy. Optics Express, 2010, 18, 25794.	3.4	40
49	Fibrillar collagen scoring by second harmonic microscopy: A new tool in the assessment of liver fibrosis. Journal of Hepatology, 2010, 52, 398-406.	3.7	157
50	Steatosis, iron and HFE genes. Journal of Hepatology, 2008, 48, 514-515.	3.7	2
51	Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. Journal of Hepatology, 2007, 46, 587-595.	3.7	67
52	Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases. Hepatology, 2006, 44, 472-477.	7.3	211
53	Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology, 2004, 39, 1639-1646.	7.3	54
54	A comparison of fibrosis progression in chronic liver diseases. Journal of Hepatology, 2003, 38, 257-265.	3.7	401

#	Article	IF	CITATIONS
55	Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology, 2002, 36, 673-678.	7.3	118
56	Histologic Features of the Liver in Insulin Resistance–Associated Iron Overload. American Journal of Clinical Pathology, 2001, 116, 263-270.	0.7	132
57	Computed tomography and magnetic resonance imaging in the diagnosis of hemochromatosis. , 2000, , 219-226.		2
58	Clinical aspects of hemochromatosis. Transfusion Science, 2000, 23, 193-200.	0.6	35
59	Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. Journal of Hepatology, 2000, 32, 727-733.	3.7	103
60	Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism. Hematology American Society of Hematology Education Program, 2000, 2000, 39-50.	2.5	8
61	Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism. Hematology American Society of Hematology Education Program, 2000, 2000, 39-50.	2.5	1
62	Magnetic Resonance Iron-Free Nodules in Genetic Hemochromatosis. American Journal of Gastroenterology, 1999, 94, 1083-1086.	0.4	22
63	A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis―on "classical― phenotypic criteria. Journal of Hepatology, 1999, 30, 588-593.	3.7	78
64	Insulin resistance–associated hepatic iron overload. Gastroenterology, 1999, 117, 1155-1163.	1.3	461
65	Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology, 1998, 115, 929-936.	1.3	306
66	Hemochromatosis after the gene discovery: revisiting the diagnostic strategy. Journal of Hepatology, 1998, 28, 14-18.	3.7	28
67	Primary liver cancer in genetic hemochromatosis: A clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology, 1993, 104, 228-234.	1.3	201
68	Liver pathology in genetic hemochromatosis: A review of 135 homozygous cases and their bioclinical correlations. Gastroenterology, 1992, 102, 2050-2059.	1.3	299
69	Liver fibrosis in genetic hemochromatosis. Journal of Hepatology, 1992, 16, 122-127.	3.7	128
70	Magnetic resonance imaging and assessment of liver iron content in genetic hemochromatosis. Journal of Hepatology, 1992, 15, 304-308.	3.7	51